<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297891</url>
  </required_header>
  <id_info>
    <org_study_id>SPAX-PBP</org_study_id>
    <secondary_id>441409627</secondary_id>
    <nct_id>NCT04297891</nct_id>
  </id_info>
  <brief_title>Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias</brief_title>
  <acronym>SPAX-PBP</acronym>
  <official_title>Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Rebecca Schule</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Neurodegenerative Diseases (DZNE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the clinical spectrum and natural progression of
      Spastic Ataxias (SPAX) and related disorders in a prospective multicenter natural history
      study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and
      therapy development and study the genetic etiology and molecular mechanisms of these
      diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a registry-based standardized prospective Natural History
      Study (NHS) in SPAX and related disorders. Participants will be seen annually. At study
      visits a standardized clinical examination will be performed including application of
      clinical rating scales (selection of rating scales may vary depending on the individual
      phenotype and specific genotype); data will be entered into a clinical database (HSP
      Registry; https://www.hsp-registry.net and ARCA Registry; www.ARCA-registry.org). At all
      study visits, patients will be asked to donate biosamples; biomaterial collection is optional
      and participants can elect to participate in sampling of blood, urine, CSF, and/or a skin
      biopsy.

      Optionally, additional examinations may be performed including imaging, quantitative movement
      analysis, neuropsychological examinations, analysis of patient or observer reported outcomes
      and OMICS analysis to characterize molecular biomarkers.

      In participants without a genetic diagnosis, next generation sequencing may be performed.

      Thus this study will establish a model of disease progression and mechanistic evolution in
      SPAX, which will allow to track and understand selective as well as overlapping dysfunction
      of the cerebellum and corticospinal tract. In a transatlantic natural history study we will
      longitudinally validate clinician- and patient-reported, digital and molecular outcomes. In
      addition, we will improve on existing and develop new outcome parameters that show superior
      sensitivity to change. These include a novel clinical SPAX composite score, a smartphone
      mHealth toolbox combining remote assessment of daily living by wearable sensors with
      app-based patient-entered outcomes (SPAX.app), and multimodal MRI radiomics with an
      innovative machine learning approach for multisite MRI analysis, including in particular the
      infratentorial space. Longitudinal validation of targeted fluid biomarker candidates will
      aslo be an important part.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Change of Scale for the Assessment and Rating of Ataxia (SARA) from baseline to 2-year follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>Severity of the ataxia component of the disease will be assessed by application of the Scale for the Assessment and Rating of Ataxia (SARA). The total score is calculated as the sum of al items, yielding a total score between 0 and 38. Hereby, higher SARA scores indicate more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Spastic Paraplegia Rating Scale (SPRS) from baseline to 2-year follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>Severity of the spasticity component of the disease will be assessed by application of the Spastic Paraplegia Rating Scale. The total score is calculated as the sum of al items, yielding a total score between 0 and 52. Hereby, higher SPRS scores indicate more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Disease severity index - Autosomal recessive spastic ataxia of Charlevoix-Saguenay(DSI-ARSACS) from baseline to 2-year follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>The DSI-ARSACS is a clinical rating scale consisting of 8 items reflecting the 3 main components of the disease (pyramidal, cerebellar, and neuropath systems) specifically developed to measure disease progression in ARSACs. The DSI-ARSACS total score can range from 0 to 38. Hereby, higher DSI-ARSACS scores indicate more severe disease.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of the Patient-Reported Outcomes Measurement Information System (PROMIS) short form &quot;physical function&quot; 12a from baseline to 2-year follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>Self-report questionnaire comprising 12 questions. All PROMIS scores are standardized (item-level calibration) and expressed as T-scores with a population mean of 50 and a Standard Deviation (SD) of 10. Higher T-scores hereby indicate a higher physical function level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of the Patient-Reported Outcomes Measurement Information System (PROMIS) short form &quot;social roles and activities&quot; 8a from baseline to 2-year follow-up</measure>
    <time_frame>24 months</time_frame>
    <description>Self-report questionnaire comprising 8 questions. All PROMIS scores are standardized (item-level calibration) and expressed as T-scores with a population mean of 50 and a Standard Deviation (SD) of 10. Higher T-scores hereby indicate a higher degree of social participation.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Spastic Ataxia</condition>
  <arm_group>
    <arm_group_label>ARSACS</arm_group_label>
    <description>Participants with genetically confirmed ARSACS (ORPHA:98) will be recruited. Target sample size for the ARSACS cohort is 120.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPG7</arm_group_label>
    <description>Participants with genetically confirmed SPG7 (ORPHA:99013) will be recruited. Target sample size for the SPG7 cohort is 72.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated healthy control</arm_group_label>
    <description>Unrelated healthy controls Healthy controls may undergo the same study procedures as the ARSACS and SPG7 cohort. Target sample size for the control cohort is 50.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical rating scale to measure Ataxia disease severity and progression</intervention_name>
    <description>SARA is a clinical scale developed by Schmitz-HÃ¼bsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.</description>
    <arm_group_label>ARSACS</arm_group_label>
    <arm_group_label>SPG7</arm_group_label>
    <arm_group_label>Unrelated healthy control</arm_group_label>
    <other_name>Scale for the Assessment and rating of Ataxia (SARA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical rating scale to measure spastic paraplegia disease severity and progression</intervention_name>
    <description>A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.</description>
    <arm_group_label>ARSACS</arm_group_label>
    <arm_group_label>SPG7</arm_group_label>
    <arm_group_label>Unrelated healthy control</arm_group_label>
    <other_name>Spastic Paraplegia Rating Scale (SPRS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)</intervention_name>
    <description>The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.
It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity.</description>
    <arm_group_label>ARSACS</arm_group_label>
    <arm_group_label>SPG7</arm_group_label>
    <arm_group_label>Unrelated healthy control</arm_group_label>
    <other_name>DSI-ARSACS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Next-Gen Sequencing (NGS)</intervention_name>
    <description>Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics</description>
    <arm_group_label>ARSACS</arm_group_label>
    <arm_group_label>SPG7</arm_group_label>
    <arm_group_label>Unrelated healthy control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      optional biosample collection including blood (DNA, serum, plasma, RNA, PBMC), urine, CSF,
      skin biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Probands with clinically manifest and genetically confirmed spastic ataxia (genetic
        subtypes: ARSACS, SPG7) will be enrolled in this study. Additionally, healthy unrelated
        controls will be enrolled; these are necessary to contrast unspecific, gender- or
        age-related findings to disease specific findings.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ARSACS cohort: genetic diagnosis of ARSACS and clinically manifest disease

          -  SPG7 cohort: genetic diagnosis of SPG7 and clinically manifest disease

          -  Unrelated healthy controls: no signs or history of neurological or psychiatric disease

        AND

          -  written informed consent provided

        AND

          -  Participants are willing and able to comply with study procedures

        Exclusion Criteria:

          -  Missing informed consent

          -  For controls: evidence of a neurodegenerative disease or movement disorders; inability
             to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca SchÃ¼le, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital TÃ¼bingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthis Synofzik, Prof., Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital TÃ¼bingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca SchÃ¼le, PD Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>85653</phone_ext>
    <email>rebecca.schuele-freyer@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthis Synofzik, Prof., Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>82060</phone_ext>
    <email>matthis.synofzik@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Neurological Institute of McGill University, Department of Neurology and Neurosurgery and Human Genetics</name>
      <address>
        <city>Montreal,</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Bernard Brais, MD, PhD</last_name>
      <phone>+1-514-398</phone>
      <phone_ext>3334</phone_ext>
      <email>bernard.brais@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Bernard Brais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ© de Sherbrooke</name>
      <address>
        <city>Saguenay</city>
        <state>Quebec</state>
        <zip>G7X 7X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Cynthia Gagnon, PhD</last_name>
      <phone>1-418-695-7700</phone>
      <email>cynthia.gagnon4@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle CÃ´tÃ©, M.Sc.</last_name>
      <phone>1-418-695-7700</phone>
      <email>Isabelle.Cote7@USherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Gagnon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DÃ©partement d'information mÃ©dicale (DIM); DÃ©partement de Biostatistique, Santn 3emÃ© Publique et Information MÃ©dicale (BIOSPIM)- BÃ¢timent Mazarie Ã©tage; HÃ´pitaux Universitaires PitiÃ© SalpÃªtriÃ¨re</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elodie Petit</last_name>
      <phone>(33)157274531</phone>
      <email>elodie.petit@icm-institute.org</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Tezenas Du Montcel, MD, PhD</last_name>
      <phone>(33) 1 42 16 05 82</phone>
      <email>sophie.tezenas@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sophie Tezenas Du Montcel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra DÃ¼rr, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Neurology &amp; Hertie-Institute for Clinical Brain Research, Dept. for Neurodegenerative Diseases</name>
      <address>
        <city>TÃ¼bingen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Selina Reich, M.Sc</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>85548</phone_ext>
      <email>selina.reich@uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Dillmann-Jehn</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>85653</phone_ext>
      <email>katrin.dillmann@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Matthis Synofzik, Prof, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca SchÃ¼le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Pisa</city>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center; Department of Neurology &amp; Donders Institute for Brain, Cognition, and Behaviour</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Bart van de Warrenburg, MD, PhD</last_name>
      <phone>0031-24-3613396</phone>
      <email>Bart.vandeWarrenburg@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Bart van de Warrenburg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KoÃ§ Univ. Hospital, KUTTAMNDAL</name>
      <address>
        <city>Istanbul</city>
        <zip>34010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Nazli BAÅAK, PhD</last_name>
      <phone>+90-850-250825023811</phone>
      <email>nbasak@ku.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Atay Vural, MD, PhD</last_name>
      <phone>+90 850 250 8250</phone>
      <email>atayvural@ku.edu.tr</email>
    </contact_backup>
    <investigator>
      <last_name>Nazli BAÅAK, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atay Vural, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Neurosciences, University of Cambridge; John Van Geest Cambridge Centre for Brain Repair</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0PY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Rita Horvath, MD, PhD</last_name>
      <phone>+44 (0) 1223 331165</phone>
      <email>rh732@medschl.cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rita Horvath, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan Reid, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://treathsp.net</url>
    <description>Website of the HSP Registry</description>
  </link>
  <link>
    <url>http://arca-registry.org</url>
    <description>Website of the ARCA Registry</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Rebecca Schule</investigator_full_name>
    <investigator_title>Principal Investigator, Leading Consultant</investigator_title>
  </responsible_party>
  <keyword>Spastic Ataxia</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Genetic etiology</keyword>
  <keyword>Molecular mechanisms</keyword>
  <keyword>Natural History Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Optic Atrophy</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

